A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after a third course of the drug…Read more - http://www.ms-uk.org/study-shows-third- ... disability
